Home › Hypopharyngeal Cancer › New York › The Bronx
Hypopharyngeal Cancer clinical trials in The Bronx, NY
3 studies for Hypopharyngeal Cancer are looking for participants at sites in and around The Bronx (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
RecruitingPhase 1
- Montefiore Medical Center-Einstein Campus, The Bronx
- Montefiore Medical Center - Moses Campus, The Bronx
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecruitingPhase 2
- Montefiore Medical Center-Einstein Campus, The Bronx
- Montefiore Medical Center-Weiler Hospital, The Bronx
- Montefiore Medical Center - Moses Campus, The Bronx
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
- Montefiore Medical Center-Einstein Campus, The Bronx
- Montefiore Medical Center - Moses Campus, The Bronx
Hypopharyngeal Cancer trials in other cities
- Atlanta, GA6 studies
- Chicago, IL6 studies
- Kansas City, MO5 studies
- Richmond, VA5 studies
- Milwaukee, WI5 studies
- Peoria, IL5 studies
- Bloomington, IL5 studies
- Joliet, IL5 studies
- Wausau, WI5 studies
- Cape Girardeau, MO5 studies
- Stevens Point, WI5 studies
- Overland Park, KS4 studies
Other studies in The Bronx
- Non-Small Cell Lung Cancer25 studies
- Breast Cancer17 studies
- Acute Myeloid Leukemia15 studies
- Lung Cancer13 studies
- Cancer (all types)12 studies
- Cardiovascular Disease12 studies
- Heart Failure11 studies
- Prostate Cancer11 studies
- Metastatic Cancer9 studies
- Colorectal Cancer9 studies
- Head and Neck Squamous Cell Carcinoma9 studies
- Myelodysplastic Syndromes9 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.